Indaptus Therapeutics (INDP) Net Cash Flow (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Net Cash Flow of -$7.0 million for Q1 2026, down 269.78% year-over-year from $4.1 million in Q1 2025, and down 2011.05% quarter-over-quarter from -$332062.0 in Q3 2025.
Indaptus Therapeutics (INDP) Net Cash Flow (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$7.0 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 269.78% year-over-year to -$7.0 million; the TTM figure through Mar 2026 stood at -$5.1 million (up 13.25% YoY), while the FY2024 annual figure was -$7.6 million, down 302.81% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$7.0 million, down from -$332062.0 in the prior quarter.
- The five-year high for Net Cash Flow was $5.9 million in Q2 2023, with the low at -$19.0 million in Q2 2022.
- The 5-year median for Net Cash Flow is -$2.2 million (2024), against an average of -$2.5 million.
- Peak annual rise in Net Cash Flow reached 206.73% in 2022, while the deepest fall reached 4057.2% in 2022.
- Indaptus Therapeutics' Net Cash Flow stood at $2.9 million in 2022, then slumped by 189.46% to -$2.6 million in 2023, then jumped by 38.74% to -$1.6 million in 2024, then soared by 79.17% to -$332062.0 in 2025, then slumped by 2011.05% to -$7.0 million in 2026.
- Business Quant data shows INDP's Net Cash Flow at -$7.0 million in Q1 2026, -$332062.0 in Q3 2025, and $2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Indaptus Therapeutics | 157.94 Mn | 146.38 Mn | - | -1.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.93 Mn |
| Jun 30, 2026 | -1.93 Mn |
| Mar 31, 2026 | -7.01 Mn |
| Mar 31, 2026 | -7.01 Mn |
| Sep 30, 2025 | -332,062.00 |
| Sep 30, 2025 | -332,062.00 |
| Jun 30, 2025 | 2.27 Mn |
| Jun 30, 2025 | 2.27 Mn |
| Mar 31, 2025 | -1.90 Mn |
| Mar 31, 2025 | -1.90 Mn |
| Dec 31, 2024 | -1.59 Mn |
| Dec 31, 2024 | -1.59 Mn |
| Sep 30, 2024 | 78,935.00 |
| Sep 30, 2024 | 78,935.00 |
| Jun 30, 2024 | -2.44 Mn |
| Jun 30, 2024 | -2.44 Mn |
| Mar 31, 2024 | -3.62 Mn |
| Mar 31, 2024 | -3.62 Mn |
| Dec 31, 2023 | -2.60 Mn |
| Dec 31, 2023 | -2.60 Mn |